Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 8/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311576 | 0.98 | MEN1 (0.45) | MEN1KMT2AALDH1A1CNR1HPGD | |
| SCHEMBL25834703 | 0.93 | MEN1 (0.47) | MEN1KMT2AALDH1A1CNR1HPGD | |
| SCHEMBL17874808 | 0.93 | MEN1 (0.47) | MEN1KMT2AALDH1A1CNR1HPGD | |
| SCHEMBL23334288 | 0.92 | MEN1 (0.50) | MEN1KMT2AALDH1A1CNR1HPGD | |
| SCHEMBL25834766 | 0.92 | MEN1 (0.50) | MEN1KMT2AALDH1A1CNR1HPGD | |
| SCHEMBL26031870 | 0.92 | MEN1 (0.50) | MEN1KMT2AALDH1A1CNR1HPGD | |
| SCHEMBL12019236 | 0.90 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1CNR1HPGD | |
| SCHEMBL26156218 | 0.90 | HPGD (0.49) | MEN1KMT2AALDH1A1CNR1HPGD | |
| SCHEMBL24919864 | 0.89 | MEN1 (0.45) | MEN1KMT2AALDH1A1CNR1HPGD | |
| SCHEMBL24530494 | 0.89 | HPGD (0.48) | MEN1KMT2AALDH1A1CNR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160333052-A1 | NOVEL CROSS-LINKED PEPTIDES CONTAINING NON-PEPTIDE CROSS-LINKED STRUCTURE, METHOD FOR SYNTHESIZING CROSS-LINKED PEPTIDES, AND NOVEL ORGANIC COMPOUND USED IN METHOD | JITSUBO CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333052-A1 | NOVEL CROSS-LINKED PEPTIDES CONTAINING NON-PEPTIDE CROSS-LINKED STRUCTURE, METHOD FOR SYNTHESIZING CROSS-LINKED PEPTIDES, AND NOVEL ORGANIC COMPOUND USED IN METHOD | NRDC, VIP, NRP1 | MEN1 3257/4885KMT2A 3705/4885ALDH1A1 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.